Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerAI sign LanguageOpen
VIPCreated with Sketch.

Impact of Adding Remdesivir to Tocilizumab in Hospitalized Patients with Coronavirus Disease

Schneider Chelsea A, Martinez Jenny, Jodoin Kathleen,Wolowich William R

Journal of Infectious Diseases and Epidemiology（2021）

Cited 0|Views3
No score
Abstract
Several treatments have been utilized in the management of COVID-19 and only remdesivir is FDA-approved at this time. Tocilizumab is an interleukin-6 antagonist that has controversial data regarding its benefits in hospitalized COVID-19 patients. Remdesivir in addition to tocilizumab has not shown any additive benefit to date; however, randomized controlled trials are in process.
More
Translated text
Key words
coronavirus,remdesivir,tocilizumab
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined